GUIDELINE INTERPRETATION
1375 Influence of SCENIC recommendations on terminology used for histopathologic diagnosis of inflammatory bowel disease-associated dysplasia
Li Y, Wang HL

REVIEW
1388 KAI1/CD82 gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers
Wang S, Chen J, Guo XZ

1406 Poorly cohesive cells gastric carcinoma including signet-ring cell cancer: Updated review of definition, classification and therapeutic management
Drubay Y, Nuydens F, Renaud F, Adenis A, Eveno C, Piessen G

1429 Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
He L, Xiao J, Zheng P, Zhong L, Peng Q

MINIREVIEWS
1446 Immunotherapy in biliary tract cancers: Current evidence and future perspectives
Uson Junior PLS, Araujo RL

1456 Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression
Zhang CY, Liu S, Yang M

1469 Angiogenesis in gastrointestinal stromal tumors: From bench to bedside
Papadakos SP, Tsagkaris C, Papadakis M, Papazoglou AS, Moysidis DV, Zografos CG, Theocharis S

1478 Stereotactic radiotherapy for intrahepatic cholangiocarcinoma
Borakati A, Froghi F, Bhogal RH, Mavroelidis VK

1490 How the COVID-19 pandemic has affected the colorectal cancer screening in Italy: A minireview

ORIGINAL ARTICLE
Basic Study
1499 Safety and feasibility of irreversible electroporation for the pancreatic head in a porcine model
Yan L, Liang B, Feng J, Zhang HY, Chang HS, Liu B, Chen YL
## Contents

**Retrospective Cohort Study**

1510  
**Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching**  

**Retrospective Study**

1528  
**Profiling of gene fusion involving targetable genes in Chinese gastric cancer**  
Liu ZH, Zhu BW, Shi M, Qu YR, He XJ, Yuan HL, Ma J, Li W, Zhao DD, Liu ZC, Wang BM, Wang CY, Tao HQ, Ma TH

1540  
**Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection**  

**Observational Study**

1552  
**Duodenal-type follicular lymphoma more than 10 years after treatment intervention: A retrospective single-center analysis**  
Saito M, Mori A, Tsukamoto S, Ishio T, Yokoyama E, Izumiyama K, Morioka M, Kondo T, Sugino H

1562  
**Evaluation of the diagnostic value of serum-based proteomics for colorectal cancer**  
Wang HJ, Xie YB, Zhang PJ, Jiang T

1574  
**RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma**  
Li J, Li H, Run ZC, Wang ZL, Jiang T, An Y, Li Z

**CASE REPORT**

1585  
**Ewing sarcoma of the ileum with wide multiorgan metastases: A case report and review of literature**  
Guo AW, Liu YS, Li H, Yuan Y, Li SX

**LETTER TO THE EDITOR**

1594  
**Exosomes: Promising biomarkers and targets for cancer**  
Fang Z, Ding YX, Li F

1597  
**Colitis and colorectal tumors should be further explored and differentiated**  
Xu DH, Zhou B, Li ZP, He LP, Wang XJ

1600  
**Acute or chronic inflammation role in gastrointestinal oncology**  
Chen HJ, Liang GY, Chen X, Du Z
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Meng Zhou, PhD, Professor, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China. zhoumeng@wmu.edu.cn

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJGO as 3.404; IF without journal self cites: 3.357; 5-year IF: 3.250; Journal Citation Indicator: 0.53; Ranking: 162 among 245 journals in oncology; Quartile category: Q3; Ranking: 59 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Gastroenterology is 72/149; Oncology is 203/360.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
August 15, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
How the COVID-19 pandemic has affected the colorectal cancer screening in Italy: A minireview

Alessandro Fancellu, Simone Veneroni, Antonio Santoru, Arianna Meloni, Valeria Sanna, Giorgio C Ginesu, Giulia Deiana, Panagiotis Paliogiannis, Chiara Ninniri, Teresa Perra, Alberto Porcu

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has caused detrimental effects on many aspects of healthcare practice. Screening programs for the commonest malignancies, namely colorectal cancer (CRC), breast cancer and cervical cancer have been discontinued or interrupted since the beginning of restriction measures aimed to limit transmission of the new coronavirus infection. Robust evidence exists in favour of the role of screening campaigns in reducing mortality from CRC. In fact, the majority of pre-malignant lesions of the colon and rectum can be diagnosed with colonoscopy and treated by endoscopic or surgical resection. Besides, colonoscopy screening allows the diagnosis of CRCs in their pre-clinical stage. Italy was one of the first European countries where a high level of COVID-19 infections and deaths was observed, and one of the first where delays in CRC prevention and early diagnosis may
translate to increased CRC-specific mortality, world healthcare systems should adopt strategies to maintain the regularity of CRC screening during subsequent peaks of the COVID-19 pandemic, or future events that might hamper screening programs.

**Key Words:** COVID-19; Colorectal cancer screening; Italy; Minireview

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Screening is a key component of colorectal cancer control. As in the rest of the world, the coronavirus disease 2019 (COVID-19) emergency has interrupted the regular delivery of cancer screening services in Italy. As a consequence, significant delays in the diagnosis and treatment of malignant and premalignant lesions have occurred, with possible effects on disease prognosis. Screening activity has gradually resumed after the first wave of the pandemic. The healthcare system is called on to be prepared to prevent the potential suspension of new rounds of screening during the COVID-19 pandemic or future extraordinary events that might hamper screening programs.

**Citation:** Fancellu A, Veneroni S, Santoru A, Meloni A, Sanna V, Ginesu GC, Deiana G, Paliogiannis P, Ninniri C, Perra T, Porcu A. How the COVID-19 pandemic has affected the colorectal cancer screening in Italy: A minireview. World J Gastrointest Oncol 2022; 14(8): 1490-1498

**URL:** https://www.wjgnet.com/1948-5204/full/v14/i8/1490.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v14.i8.1490

**INTRODUCTION**

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males, the second in females, and the second leading cause of cancer death. Although incidence and mortality vary between countries, according to GLOBOCAN estimates, worldwide, the year 2020 saw 1.93 million new CRC cases diagnosed and 0.94 million deaths caused by CRC. The incidence of the disease is increasing in high-income countries, where it has traditionally been higher, as well as in middle- and low-income countries[1,2]. Robust evidence exists about the role of screening programs in reducing mortality from CRC. CRC screening includes a faecal occult blood test (FOBT) to detect blood in stool that may originate from a neoplastic or pre-neoplastic lesion, as well as colonoscopy. The latter allows either biopsy of early CRC or lesion removal at the time of the test.

In the last 2 years, population screening programs for the commonest cancers have been devastated by the spread of the coronavirus disease 2019 (COVID-19) pandemic[3-7]. In fact, screening has been deprioritized as healthcare resources have been reoriented toward treatment and prevention of the new coronavirus infection. Besides, many people have avoided hospitals and screening services for fear of contracting COVID-19.

Italy was one of the first countries in Europe to be affected by COVID-19, and measures taken to contain the spread of COVID-19 infection were more restrictive than those in other countries from the onset of the pandemic.

This review aims to critically evaluate the impact of the COVID-19 outbreak on CRC screening programs in Italy. We also discuss projected effects of delayed CRC diagnosis and treatment due to discontinuation of screening.

**LITERATURE SEARCH AND STUDY SELECTION**

The present review focused on the literature covering the topic of CRC screening in Italy during the COVID-19 era. A systematic literature search using the PubMed, Scopus, Web of Science, and Reference Citation Analysis databases was conducted in February 2022. The following keywords were used and combined for the search: ‘colorectal’, ‘colon’, ‘rectal’, ‘cancer’, ‘carcinoma’, ‘malignancy’, ‘screening’, ‘screening program’, ‘COVID’, ‘COVID-19’, ‘SARS-CoV-2’, ‘coronavirus’, ‘Italy’ and ‘Italian’. Articles published in English from January 1, 2020 to January 31, 2022 were retrieved, screened and selected by two independent authors. Relevant data were extracted into a standardized data collection sheet by three authors. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses[8] guidelines were used to create a flowchart, which is shown in Figure 1.

The final inclusion criteria were observational retrospective studies, surveys or national and regional database-based studies that presented numerical analyses and comparisons of CRC screening results.
between the COVID-19 and pre-COVID-19 eras.

At the time of this review, a total of seven articles had been finally selected from a comprehensive number of 563 published studies\[6,7,9-13\]. The included articles are briefly summarized in Table 1. The outcomes were defined as percentages or overall proportions. Due to the nature of the work (minireview), no formal statistical analyses were conducted. Most of the studies (71%) focused their attention on the first semester of 2020, coinciding with the first COVID-19 burst in Italy\[7,9,11-13\]. The remaining two articles (29%) analysed a broader time frame of almost the entire year of 2020\[6,10\]. No articles were found concentrating on the 2021 situation, even though the pandemic was ongoing in its third and fourth waves. The studies ranged from single-unit experiences\[7\] to nation-wide surveys including all Italian regions\[9\] or evaluating more than 100 units across the country\[12\]. All of them focused on the reduction of endoscopic screening exams for CRC and the decrease in CRC new diagnoses in the analysed period with respect to the same temporal window in the previous years, namely 2018 and 2019.

**EPIDEMIOLOGY OF CRC AND SCREENING PROGRAMS IN ITALY**

According to the Italian Minister of Health, in the year 2020, about 43700 people were diagnosed with CRC (20282 women and 23420 men), and about 20000 died from the disease\[14\]. The 5-year survival rate for CRC in Italy is 65.3% in men and 65.3% in women\[15\]. CRC is one of the most preventable of all cancers, and regular screening is one of the most powerful preventive tools. Screening is the process of looking for cancer or precancerous lesions in people asymptomatic for the disease. The key usefulness of screening is that most CRCs develop following the so called ‘adenoma-carcinoma sequence’. Benign adenomatous polyps usually take several years to develop into CRC. With regular screening, most polyps can be detected and safely removed before they turn into forms of invasive carcinoma. Besides, screening can permit the diagnosis and treatment of early forms of CRC, thus increasing the possibility of a cure. The main aim of CRC screening is to decrease mortality from the disease\[15-17\]. There is evidence that the introduction of CRC screening programs in the early 2000s has substantially reduced mortality rates in European countries\[18-21\]. In Italy, CRC screening programs organized by the public health system cover the population of the entire country. In most regions, a FOBT by the immunochemical technique is offered every 2 years to all men and women aged 50–69 years, who are at the highest risk of developing the disease. In some regions, such as Piedmont, flexible sigmoidoscopy or FOBT are offered once in a time to people aged 58–69 years. The widespread use of FOBT in Italy has led to a progressive reduction in the incidence and mortality from CRC, the latter thanks to detection of CRC in its early stage. Data from 48 cancer registries from 17 Italian regions reported a reduction in the CRC incidence rate from 104.3 and 64.3 per 100,000 in the year 2003 to 89.9 and 58.4 per 100,000 in 2014 in men and women, respectively. Besides, in the same time frame, mortality rates decreased from 41.1 to 39.2 per 100,000 in men and from 24.6 to 23.1 per 100,000 in women\[15\]. Data from randomized studies have demonstrated that both FOBT and flexible sigmoidoscopy have proven efficacy in reducing mortality from CRC by 22% and 28%, respectively\[15,22\]. In Italy, the most often used approach to CRC screening is to invite the target population by mail to undergo FOBT. Men and women with negative
### Table 1: Studies reporting on the effects of coronavirus disease 2019 pandemic on colorectal screening in Italy

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Centers participating in the study</th>
<th>Time frame</th>
<th>Main conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Armariol et al.[8]</td>
<td>20 out of 21 regions involved</td>
<td>January-May 2020 vs January-May 2019</td>
<td>(1) Cumulative delay of colorectal screening = 585,287 less exams (54.9%); (2) Esteemed delay of diagnosis of 3956 high-risk colonic adenomas and 616 colon cancer cases; and (3) Esteemed delay in diagnosis of 2.7 mo</td>
</tr>
<tr>
<td>Germana et al.[10]</td>
<td>Veneto regional screening database</td>
<td>January-November 2020 vs same period in 2018-2019</td>
<td>(1) 458,877 people invited to undergo FOBT, within the regional colorectal cancer screening program, 115,976 fewer than the previous two years (-20.4%), with an adherence rate that dropped from 65.2% to 54.2%; (2) Colonoscopies fell by 22.2% (67,138 in 2020 ss. 86,298 for the years 2018-2019); and (3) The reduction was of 13.1% for screening colonoscopies following a positive FOBT, and 24.9% for non-screening colonoscopies</td>
</tr>
<tr>
<td>Buscarini et al.[6]</td>
<td>49 units across Italy: 32 from the North (65.3%), 6 from the Center (12.2%), and 11 from the South (22.4%)</td>
<td>January-October 2020 vs same period in 2017, 2018 and 2019</td>
<td>(1) CRC new diagnoses decreased by 11.9%; and (2) The 2019-2020 comparison showed fewer CRC diagnoses in the North (-13.7%), Center (-16.5%) and South (-4.1%)</td>
</tr>
<tr>
<td>Ferrara et al. [11]</td>
<td>7 Units in Northern-Central Italy</td>
<td>11th-20th week of 2020 vs same period in 2018 and 2019</td>
<td>Decrease of 46.6% of new colorectal cancer diagnosis with screening program (335 in 2018-2019 and only 178 in 2020)</td>
</tr>
<tr>
<td>De Vincentiis et al.[7]</td>
<td>Single Unit audit</td>
<td>11th-20th week of 2020 vs same period in 2018 and 2019</td>
<td>CRC new diagnoses fell in 2020 by 62% compared with the average number in 2018 and 2019. CRC was identified as carrying a potentially important diagnostic delay</td>
</tr>
<tr>
<td>Maida et al.[12]</td>
<td>121 Units from 20 Italian regions</td>
<td>Survey between March 30, 2020 and April 7, 2020</td>
<td>(1) 49 (46.7%) of 105 gastroenterology divisions had suspended their endoscopic screening program for colorectal cancer during the COVID-19 pandemic; (2) Overall, 10.7% Gastroenterology Divisions have been converted to Covid Units; and (3) Endoscopic procedures were limited to urgencies and oncology indications</td>
</tr>
<tr>
<td>Repici et al.[13]</td>
<td>41 EUs across Northern Italy</td>
<td>Survey between March 16, 2020 and March 31, 2020</td>
<td>(1) 75%-99% reduction in activity in 28% of endoscopic units, a 50%-75% reduction in 9% of units, with only a single unit maintaining its workload unchanged; and (2) Most EUs limited their activity to urgent cases, including patients at high-risk of cancer</td>
</tr>
</tbody>
</table>

EUs: Endoscopic Units; CRC: Colorectal cancer; COVID-19: Coronavirus disease 2019; FOBT: Faecal occult blood test.

FOBT are recalled to repeat the test 2 years later. Those who do not respond to the first call are contacted by mail a second time within 6 mo. Patients with positive FOBT are contacted by phone to undergo a total or virtual colonoscopy (computed tomography colonography) in the case of incomplete colonoscopy[15]. When colonoscopy or sigmoidoscopy detects neoplasms, patients are directed to surgery or endoscopic surgery and enrolled in a follow-up program. Despite being a less tolerated and operator-dependent examination, colonoscopy leads to a complete exploration of the entire colorectal lumen and is much more sensitive than flexible sigmoidoscopy, based on indirect evidence and observational studies[23].

### EPIDEMIOLOGY OF COVID-19 IN ITALY

Italy was the first European nation to be affected by COVID-19. The first Italian cases of COVID-19 date back to January 30, 2020, when two tourists tested positive by nasopharyngeal COVID-19 Test in Rome. In February 2020, in the city of Codogno, located in the Northern region of Lombardy, a 38-year-old man was hospitalized for respiratory symptoms and tested positive; the day after, 60 cases of COVID in Codogno were diagnosed[24]. During this first COVID-19 wave, the Italian Healthcare Service was near collapse, registering in just 1 mo almost 40000 total cases and 3000 deaths (March 2020)[25]. From then onwards, Italy underwent three further pandemic waves, like most other countries in Europe. In that period, the development of vaccines contributed dramatically to proper management of the pandemic crisis[26]. As of March 14, 2022, 13402905 positive cases were registered in Italy, including 12242669 discharged and healed people, 156997 deaths and 1003239 active cases[27]. Italy ranks 9th in the world and 5th in Europe for the total number of cases, and 8th in the world and 3rd in Europe for the absolute number of deaths. Furthermore, Italy ranks 53rd in the world for total cases per capita and 25th for total deaths per capita[26].
EFFECTS OF THE COVID-19 PANDEMIC ON CRC SCREENING IN ITALY

The DECOR-19 DElayed CRC care during the COVID-19 Pandemic was a global perspective from an international survey, where the highest number of respondents (1051) were from Italy. Of note, endoscopic procedures for CRC were the diagnostic techniques most affected by the COVID-19 emergency (73.7% of respondents). CRC surgery was delayed in 58.3% of institutions. For 90% of respondents, the delay was 5–8 wk beyond the normal wait time and for the remaining 10%, more than 8 wk.[28].

The Italian National Screening Observatory reported on the accumulated delay experienced by organized screening programs up to May 2020. In the first 5 mo of 2020 vs the same period of 2019, 585287 fewer CRC screening exams were conducted, accounting for a 54.9% decrease[9]. Based on these numbers, an estimated 1168 CRCs and 6667 advanced adenomas would have been missed in the period from January 2020 to September 2020[29].

A survey was conducted by the National Centre for Screening Monitoring on cervical, breast and CRC screening activities conducted in 2020. Screening tests for CRC decreased by 45.5% in 2020 compared with 2019, with an estimated 1299 CRC cases going undiagnosed. Interestingly, participation in CRC screening programs decreased by 20%.[30].

In a study investigating the Cancer Diagnostic Delay in Northern and Central Italy During the 2020 lockdown, a comparison was made among the number of first pathologic diagnoses of malignancy made from weeks 11 to 20 (April and May) of 2018, 2019 and 2020 at seven pathology units serving secondary care hospitals in Northern-Central Italy. A consistent decrease of 46.6% in new CRC cases diagnosed by screening programs (335 in 2018–2019 and only 178 in 2020) was observed.[11].

The number of people who responded to invitations for FOBT screening in the region of Veneto in 2020 was about 16000 less than in the previous 2 years, with an adherence rate that decreased from 65.2% to 54.2%. Colonoscopies fell by 22.2% (67138 in 2020 vs 86298 for the period 2018–2019); the rate reached its lowest in April (-70.4%). There was a 13.1% reduction in screening colonoscopies following a positive FOBT and a 24.9% reduction in non-screening colonoscopies (P < 0.001) [10].

In a national survey, CRC diagnoses decreased by 11.9% from 2019 to 2020. A comparison between 2019 and 2020 showed fewer CRC diagnoses in the North (-13.7%), Center (-16.5%) and South (-4.1%) [6]. The authors performed an audit to evaluate the impact of COVID-19 pandemic-related delays in the diagnosis of major cancers at a Pathology Unit of a Secondary Care Hospital Network in Italy[7]. Cancer diagnoses fell in 2020 by 39% compared with the average number recorded in 2018 and 2019, and CRC was the tumour type with the greatest decrease.

A multicentric study evaluated the impact of the 2019 outbreak on 41 Italian endoscopic units. In 27 (65.9%) units, endoscopists were relocated to other hospital departments. In 31 (75.6%) units, nurses were relocated to other hospital departments. Most endoscopy units limited their activity to urgent cases, also including patients at high risk of cancer. After the COVID-19 outbreak, 39 endoscopy units (95.1%) continued to perform urgent procedures, 39 (95.1%) continued inpatient procedures and 28 (68.3%) continued screening colonoscopies for CRC. In quantitative terms, this corresponded to a 75–99% reduction in activity in 28% of endoscopic units and to a 50%–75% reduction in 9% of units, with only a single unit maintaining its workload unchanged. Finally, most EUs limited their activity to urgent cases, including patients at high risk of cancer[13].

Examining Gastroenterology Divisions in Italy, a national survey that analysed data between March and April 2020 underscored that 46.7% of gastroenterology divisions had suspended their endoscopic screening programs for CRC during the COVID-19 pandemic, 10.7% of Gastroenterology Divisions had been converted to COVID units, and 39 (95.1%) continued to perform urgent procedures, 39 (95.1%) continued inpatient procedures and 28 (68.3%) continued screening colonoscopies for CRC. In quantitative terms, this corresponded to a 75–99% reduction in activity in 28% of endoscopic units and to a 50%–75% reduction in 9% of units, with only a single unit maintaining its workload unchanged. Finally, most EUs limited their activity to urgent cases, including patients at high risk of cancer[13].

Similar data were reported from countries outside Italy. In South Australia, the total number of colonoscopies decreased by 51.1% from 2019 to 2020[31]. In the United Kingdom, endoscopic cancer detection was reduced by 58% overall and by 72% for CRC in particular during the period impacted by COVID (March–May 2020)[32]. In France, roughly 250000 fewer colonoscopy preparations were dispensed during the first 6 mo of the COVID-19 pandemic[33]. In Hong Kong of China, the mean number of lower endoscopies performed per week decreased by 51.0% after the beginning of the pandemic[34]. The number of obstructive CRCs in Japan has increased during the COVID-19 pandemic, as a possible consequence of CRC screening discontinuation[35].

CONSEQUENCES OF REDUCED CRC SCREENING ACTIVITY

This review demonstrates the remarkable impact of the pandemic on endoscopic services in Italy. Interruption and discontinuation of CRC screening inevitably translated into a substantial and concerning reduction in CRC detection. It is commonly believed that screening delays beyond 4–6 mo would significantly increase advanced CRC cases and, if lasting beyond 12 mo, mortality as well[15]. In patients with CRC, 3–10-year survival is lower if treatment is started > 90 d from diagnosis, and similar data are reported for other cancers[36]. The ideal timing of resection of colon cancer specifically has been estimated to be between 3 and 6 wk from diagnosis, which is unlikely to be achieved during the
COVID-19 outbreak[37]. In a study where patients who underwent surgery for CRC in the pre-COVID-19 era (October 2019–February 2020) were compared to those who did so after the end of the second wave (January 2021–May 2021), an increase in T4 tumours with higher preoperative levels of CEA and CA 19-9 was observed. These tumours required more extensive lymph node dissection. The authors speculated that this finding could be attributed to the reduced number of colonoscopies performed during the lockdown, as well as to patients’ fears of potential infections in the hospital setting[37].

A survey by the Italian Federation of the Digestive Diseases Societies found that in gastroenterology units, 11.9% fewer CRC cases were diagnosed between January 1, 2020 and October 31, 2020, compared with the same period in 2019[6].

Surgical oncology services around the world suffered a remarkable reduction in activity, resulting in a doubling of waiting lists as a result of delays in the screening and diagnosis of CRC due to the restrictions imposed by the pandemic.

A study was designed to evaluate the effects of COVID-19-related delays in CRC screening in 20 hospitals of Northern Italy by comparing 1755 patients who underwent CRC surgery in 2019 vs 1481 in 2020. The results showed that CRCs in 2020 (compared to 2019) were more likely to be symptomatic [OR: 1.36 (95%CI: 1.09-1.69)], to be clinical stage T4 [OR: 1.38 (95%CI: 1.03-1.85)] and to have multiple liver metastases [OR: 2.21 (95%CI: 1.24-3.94)], although they were not more likely to be associated with surgical complications [OR: 0.79 (95%CI: 0.68-0.93)][38]. In particular, locally advanced disease, as well as the presence of CRC metastases to the liver, are definite prognostic factors in patients affected by CRC.

Another study evaluated the impact of the COVID-19 emergency on elective oncological surgical activity in 54 surgical units in Italy, including 11 colorectal units. Among the latter, 9 (82%) experienced a reduction of their surgical activity by 60%, with an expected prolongation of 5 wk between multidisciplinary meetings and surgery[39].

In the absence of proper catch-up campaigns aiming to recuperate those who missed their scheduled screening, the prognosis of patients with CRC could worsen. In fact, the long-term effects of the delay in CRC diagnosis due to interruption of screening activity could result in a rise in late-stage CRC cases and eventually in an undesirable loss of life years due to the lack of appropriate treatments for these patients[40].

Based on a procedural model using real-world data, in Italy a significant increase in deaths (12%) can be estimated at 5 years after a delay of longer than 12 mo in access to colonoscopy. In particular, in a study comparing baseline (0–3 mo), moderate (7–12 mo) and long (> 12 mo) delays, a significant increase in advanced CRC (from 26% to 29% and 33%, respectively, was seen. Thus, the authors have estimated a significant increase in the total number of deaths (12.0%) when moving from a 0–3-mo to a >12-mo delay \((P < 0.005)\) and a significant change in the mortality distribution by stage from baseline to >12 mo \((P < 0.001)\)[41,42].

**CONCLUSION**

The results of our review confirm that the COVID-19 emergency has caused detrimental effects on CRC screening programs in Italy, similarly to what occurred in other counties on all continents. In most hospitals and territorial healthcare services, a time-limited suspension of CRC screening services was observed. At the time of writing, the situation is different from that observed at the beginning of the COVID-19 crisis. Indeed, advances in the treatment of patients affected by COVID-19, as well as prevention with massive vaccine campaigns, has significantly decreased the growth in the total number of cases and rates of hospitalization. As a consequence, screening activity has now resumed in many Italian regions. Nonetheless, sporadic COVID-19 outbreaks due to the diffusion of new variants of the virus continue to modify the activities of healthcare services, and the duration of the effects of the COVID-19 pandemic on social life and healthcare in general is difficult to predict. The delayed diagnoses of CRC cases attributable to screening discontinuation is expected to result in an increase in advanced cancer cases—and possibly deaths—in the coming years. It is of the utmost importance that healthcare services of countries around the world develop reliable policies to maintain standard CRC screening activity in the presence of new pandemic outbreaks or similar extraordinary events.

**FOOTNOTES**

**Author contributions:** Fancellu A conceived the paper and drafted the manuscript; Veneroni S made the literature search and contributed to the drafting of the manuscript; Santoru A and Meloni A searched the web sources for relevant issues regarding the topic of the article; Ginesu GC critically resumed the data from the studies; Deiana G contributed to the literature search; Paliogiannis P contributed to critically evaluate the literature data; Ninniri C participated in the analysis and interpretation of the data; Perra T revised the article critically for important intellectual content; Sanna V prepared the figures and tables; Porcu A coordinated and supervised the writing of the paper.
REFERENCES


28 [cited 10 March 2022]. Available from: http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1


35 Lui TKL, Leung K, Guo CG, Tsui VWMM, Wu JT, Leung WK. Impacts of the Coronavirus 2019 Pandemic on Gastrointestinal Endoscopy Volume and Diagnosis of Gastric and Colorectal Cancers: A Population-Based Study. *Gastroenterology* 2020; 159: 1164-1166.e3; DOI: 32425228; DOI: 10.1053.j.gastro.2020.05.037


Fancellu A et al. COVID-19 and CRC screening in Italy


